Skip to main content
OpenTrials
Completed

NCT Number: NCT00405288

The Safety of Proctofoam-HC in the Third Trimester of Pregnancy

The purpose of this study is to evaluate the fetal safety of topical application of Proctofoam-HC®, an antihemorrhoidal, in the third trimester of pregnancy.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Mount Sinai Hospital, Toronto, Ontario, Canada

Loading trial locations.

About this study

Hemorrhoids are a frequent condition in pregnancy. The rate is increased as pregnancy progresses, and they affect up to 24% of pregnant women in the third trimester. Complications of untreated hemorrhoids include bleeding, prolapse, soiling, discharge with perianal irritation and itching, and in severe cases, severe pain and venous engorgement which could even lead to thrombosis and infarction. Hemorrhoids are treated with a variety of suppositories and gels, based on analgesic and anti-inflammatory effects. The safety of these antihemorrhoidal products has not yet been documented in pregnant women.

Proctofoam-HC® has been on the Canadian market for 25 years. It combines the anti-inflammatory action of hydrocortisone with the surface anesthetic effect of pramoxine HCl. It is approved for temporary relief of anorectal inflammation, pruritus, pain and swelling associated with haemorrhoids, fissures, pruritus ani, cryptitis, proctitis and postoperative pain.

We hypothesize that local application of Proctofoam-HC® in the third trimester of pregnancy is safe for the mother and fetus.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • For intervention group, any pregnant woman with a primary anorectal condition during the third trimester of pregnancy
  • For control group, women in third trimester of pregnancy not treated with Proctofoam, and matched on maternal age and smoking status
  • for either group,no other pregnancy complications

Exclusion criteria

  • exposure to known teratogens during pregnancy as evident either during the prenatal or postnatal interview
  • insufficient English language skills to understand the questionnaires and assessment material
  • Women who have received other corticosteroid medications (systemic or topical)during pregnancy
  • Women with the following conditions: abscess, fistula, tuberculosis, varicella, acute Herpes Simplex or fungal infection
  • age less than 18 years
  • History of previous reaction to any of the product's components, such as: local irritation, hypertrichosis, hypopigmentation, etc.
  • Known Intrauterine Growth Restriction (IUGR) or a chronic state that may cause IUGR (SLE, placental insufficiency).
  • Multi fetal pregnancy
  • Binge alcohol consumption (5 or more drinks on one occasion,in a row or within a short period of time)

Treatment and study plan

Proctofoam-HC®

Drug

Observational study of the exposure to Proctofoam-HC®

Other names: 1% Pramoxine+1% Hydrocortisone ( Proctofoam-HC®)

Primary outcomes

  1. Birth-weight

    Time frame: until delivery

    Weight of the baby measured in grams at time of birth.

Secondary outcomes

  1. Gestational Age at Delivery

    Time frame: until delivery

    Fetal gestational age at delivery

  2. Mode of Delivery

    Time frame: at birth

    Method of delivery for both groups: vaginal or caesarean section

  3. Prematurity

    Time frame: at birth

    birth at <37 gestational weeks

  4. Fetal Distress

    Time frame: at birth

    Presence of fetal distress at birth: heart deceleration/acceleration, meconium/amniotic fluid

  5. Low Birth Weight at Birth

    Time frame: at birth

    Low birth weight (birth weights <2500 grams)

  6. Neonatal Health

    Time frame: at birth

    Neonatal health at birthyes=need for medical attention or intervention after birth, abnormalities detected, no= no need for medical attention, no abnormalities detected at birth

Sponsors and collaborators

Lead sponsor

The Hospital for Sick Children

Other

Collaborators

  • Duchesnay Inc.

Registry information

Important dates

Study start
2006
Primary completion
2009
Study completion
2010
First posted
Nov 30, 2006
Registry last updated
Feb 5, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.